The FDA has approved trastuzumab deruxtecan (T-DXd) for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer based on DESTINY-Breast06 trial results. #BreastCancer #Oncology https://ascopost.com/news/january-2025/t-dxd-approved-by-the-fda-for-pretreated-patients-with-her2-low-or-ultralow-metastatic-breast-cancer/
Post image

Comments

Posting Rules

  • Be respectful to others
  • No spam or self-promotion
  • Stay on topic
  • Follow Bluesky's terms of service